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Chemotherapy remains the standard treatment for acute myeloid leukemia; however, the emergence of drug resistance is a major 
hurdle in the successful treatment of leukemia. The expression of multidrug resistance-associated protein 4 (MRP4) induces re-
sistance in the adriamycin-resistant acute myeloid leukemia cell line, K562/ADR. The aim of this study was to investigate whether 
knockdown of MRP4 by lentivirus-mediated siRNA could improve the sensitivity of K562/ADR cells to adriamycin. Five lenti-
virus-mediated short hairpin RNAs (lv-shRNAs-MRP4) were designed to trigger the gene silencing RNA interference (RNAi) 
pathway. The efficiency of lentivirus-mediated siRNA infection into K562/ADR cells was determined using fluorescence mi-
croscopy to observe lentivirus-mediated GFP expression. MRP4 expression in infected K562/ADR cells was evaluated by real- 
time PCR and Western blot analysis. The MTS assay was used to measure cell viability and flow cytometry was used to measure 
apoptosis. The transfection efficiency of K562/ADR cells was over 80 percent. The gene silencing efficacy of lv-shRNA1-MRP4 
was superior to the other constructs. Infection of K562/ADR cells with lv-shRNA1-MRP4 led to strong inhibition of MRP4 
mRNA and protein expression. Combined treatment with lv-shRNA1-MRP4 and adriamycin decreased cell growth and increased 
apoptosis compared to treatment with lv-shRNA1-MRP4 or adriamycin alone. These data indicate that in K562/ADR cells MRP4 
is involved in drug resistance mechanisms and that lentivirus-mediated knockdown of MRP4 may enhance sensitivity to adriamycin. 
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Acute myeloid leukemia (AML) is a clonal disorder, char-
acterized by the accumulation of an immature cell popula-
tion in the bone marrow and/or peripheral blood. Despite 
improvements over the last 30 years in the combined use of 
various cytarabine (Ara-C) and anthracycline agents, the 
overall prognosis for AML remains poor. A major issue in 
the treatment of AML is multidrug resistance (MDR) [1]. 
Therefore, reversal of multi-drug resistance in leukemia 
cells is important to effectively treat AML patients [2,3].  
Multidrug resistance-associated protein (MRP) is an 
ATP-binding cassette (ABC) transporter protein that is re-
sponsible for the pump resistance in various cancer cells. 
Over-expression of ABC transporters is commonly seen in 
MDR. MRP4 is a member of the C subfamily of ABC 
transporters. The first functional properties of MRP4 were 
described in a human T-lymphoid cell line in 1999. MRP4 
is noteworthy for a particularly broad substrate specificity, 
including antiviral, antibiotic, cardiovascular and cytotoxic 
agents and it is a new therapeutic target for the modulation 
of various pathophysiological signaling processes [4,5]. 
Studies have shown that high levels of MRP4 expression, 
but not of any other MRP gene, were significantly associated 
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with poor outcome in neuroblastoma [6]. MRP4 was also 
identified as a marker for immature stem cells in acute leu-
kemia patients [7]. Moreover, the expression level of MRP4 
in 6-mercaptopurine resistant CEM-MP5 leukemia cells was 
approximately 4-fold higher compared with that in parental 
CEM cells [8]. However, the importance of MRP4 in adri-
amycin-resistant acute myeloid leukemia cell lines is un-
known. Our previous experiments have shown that MRP4 is 
over-expressed in K562/ADR cells relative to parental 
K562 cells (Figure 1). Thus, we determined whether 
knockdown of MRP4 using RNAi could reverse resistance 
and sensitize K562/ADR cells to adriamycin. 
As with any cancer therapy, effective delivery of the 
therapeutic agent to the proper target is a rate limiting factor 
and this holds true for the RNA interference (RNAi) path-
way [9]. RNAi strategies that have been employed in cancer 
gene silencing include delivery of double stranded RNA 
complexes (siRNA), the use of double stranded DNA vec-
tors encoding short hairpin-containing RNA sequences 
(shRNA), or the use of viral vectors containing double- 
stranded DNA encoding shRNA sequences. Viral vectors 
are particularly attractive because they can induce long-term 
knockdown of gene transcripts in vivo. Thus, the use of 
RNAi in a stable viral vector system, such as the lentivirus, 
is a possible strategy for stable gene knockdown [10–12]. 
Studies have demonstrated that RNAi is a valid approach to 
counter cellular drug resistance mediated by ABC trans-
porters [2] and that RNAi has therapeutic potential in leu-
kemia cell lines [13]. 
Our results suggest that MRP4 is a candidate molecule 
for mediating adriamycin resistance in acute myeloid leu-
kemia cells. In addition, lentiviral-mediated siRNA target-
ing MRP4 provides an excellent approach for delivering 
siRNA into K562/ADR cells and this approach may be used 
for gene therapy of AML to produce an anti-proliferative 




Figure 1  Western blot analysis of MRP4 levels. Compared to parental 
K562 cells, K562/ADR cells express a higher level of MRP4 protein. 
GAPDH, internal control protein. 
1  Materials and methods 
1.1  Drugs and cell culture   
Adriamycin (Sigma, St.Louis, USA) was dissolved in dis-
tilled water and stored at –30°C until use. Adriamycin-  
selected human erythroid blast crisis chronic myeloid leu-
kemia (K562/ADR) cells were obtained from the Shanghai 
Institute of Cell Biology, Chinese Academy of Sciences. 
Parental K562 cells were provided by the Central Labora-
tory of the First Affiliated Hospital of Lanzhou University 
(Lanzhou, China). Cells were routinely maintained in 
RPMI-1640 medium supplemented with 10% fetal calf se-
rum (FCS), 2 mmol/L L-glutamine, and 1% antibiotics (100 
IU/mL penicillin, 100 µg/mL streptomycin) under a humidi-
fied atmosphere of 5% CO2 and air at 37°C. K562/ADR 
cells were incubated in adriamycin-free medium for over 1 
week before experimentation. The IC50 value of K562/ADR 
was (60.33 ± 10.68) µg/mL. 
1.2  Design of siRNA 
Five MRP4-specific sequences (5-CGTCCTTGTTAACT- 
CTTCA-3; 5-CTGGTACTTAGGAATTTAT-3; 5-GGT- 
TGCCTATGTGCTTCAA-3; 5-GAGCTGAGAATGACG- 
CACA-3; 5-CTGGTACTTAGGAATTTAT-3) were cho-
sen according to general recommendations (http://www. 
ambion.com/techlib/misc/siRNA_finder.html) using MRP4 
reference sequences (GenBank Accession No. NM_005845). 
The negative control siRNA sequence was 5-TTCTCCGA- 
ACGTGTCACGT-3, which was not homologous to any 
human DNA sequence. The siRNAs were designed and 
synthesized by GeneChem (Shanghai, China).  
1.3  Construction of lentivirus-mediated short hairpin 
RNA (lv-shRNA) 
The pGCL-GFP lentiviral vector containing a CMV driven 
GFP reporter and a U6 promoter upstream of cloning re-
striction sites (Hpa I and Xho I), which allow the introduc-
tion of oligonucleotides encoding shRNAs, has been previ-
ously described [14]. Sense and antisense oligonucleotides 
were designed for 5 targeting sequences (Table 1). The oli-
gonucleotides were annealed and ligated into the Hpa I and 
Xho I sites of pGCL-GFP. Each shRNA consists of a T, a 
21-nt sense sequence, a short spacer (TTCAAGAGA), the 
antisense sequence, 6 Ts (a stop signal for RNA polymerase 
III), and an Xho I site [15]. pGCL-GFP-shRNA-MRP4 con-
structs were then propagated and purified using a QIAfilter 
Plasmid Maxi Kit (Qiagen, Germany). Correct insertions of 
shRNA cassettes were confirmed by restriction mapping 
and direct DNA sequencing. The new engineered vectors 
were called lv-shRNA-MRP4; the negative control was 
named lv-shRNA-NC. The ability of the five lv-shRNA- 
MRP4 vectors to knock down MRP4 was investigated using 
92 Liu B, et al.   Chin Sci Bull   January (2012) Vol.57 No.1 
Table 1  shRNA template sequences 
shRNA 5 Stem Loop Stem 3 
shRNA1-antisense Ccgg taCGTCCTTGTTAACTCTTCA TTCAAGAGA TGAAGAGTTAACAAGGACGta TTTTTg 
shRNA1-sense aattcaaaaa taCGTCCTTGTTAACTCTTCA TCTCTTGAA TGAAGAGTTAACAAGGACGta  
shRNA2-antisense Ccgg aaCTGGTACTTAGGAATTTAT TTCAAGAGA ATAAATTCCTAAGTACCAGtt TTTTTg 
shRNA2-sense aattcaaaaa aaCTGGTACTTAGGAATTTAT TCTCTTGAA ATAAATTCCTAAGTACCAGtt  
shRNA3-antisense Ccgg  caGGTTGCCTATGTGCTTCAA TTCAAGAGA TTGAAGCACATAGGCAACCtg TTTTTg 
shRNA3-sense aattcaaaaa caGGTTGCCTATGTGCTTCAA TCTCTTGAA TTGAAGCACATAGGCAACCtg  
shRNA4-antisense Ccgg aaGAGCTGAGAATGACGCACA TTCAAGAGA TGTGCGTCATTCTCAGCTCtt TTTTTg 
shRNA4-sense aattcaaaaa aaGAGCTGAGAATGACGCACA TCTCTTGAA TGTGCGTCATTCTCAGCTCtt  
shRNA5-antisense Ccgg aaCTGGTACTTAGGAATTTAT TTCAAGAGA ATAAATTCCTAAGTACCAGtt TTTTTg 
shRNA5-sense aattcaaaaa aaCTGGTACTTAGGAATTTAT TCTCTTGAA ATAAATTCCTAAGTACCAGtt  
 
real-time PCR. 
1.4  Lentivirus production and concentration 
Recombinant lentiviruses were produced by co-transfecting 
293T cells with a lentivirus expression plasmid and a pack-
aging plasmid using Lipofectamine 2000 [16–19]. Infec-
tious lentiviruses were harvested 48 h post-transfection, 
centrifuged to remove cell debris, and then filtered through 
0.45 µm cellulose acetate filters [15–18]. Virus titer was 
determined by fluorescence-activated cell sorting analysis 
of GFP positive 293T cells and was approximately 2×109 
transducing units (TU)/mL medium. 
1.5  Fluorescence microscopy  
To determine the infection efficiency of K562/ADR cells 
with lv-shRNA-MRP4 and lv-shRNA-NC, cells expressing 
GFP protein were observed using fluorescence microscopy 
(Olympus, Tokyo, Japan) 5 d after transfection and images 
were captured. Successfully infected K562/ADR cells were 
collected for subsequent experiments.  
1.6  Quantitative real-time RT-PCR  
Cells were divided into 3 groups: control cells (CON, 
K562/ADR cells without transfection), lv-shRNA-NC cells 
(NC) and lv-shRNA-MRP4 cells (Knockdown cells, KD). 
Five days post-infection, total RNA was extracted from 
transfected K562/ADR cells with TRIzol (Invitrogen, Cali-
fornia, USA). Reverse transcription (RT) was performed 
using a Reverse Transcriptase Kit (Promega, Bejing, China). 
Actin was used as an endogenous control. Real-time PCR 
was performed in triplicate using SYBR Mastermix on a 
TP800 (TaKaRa, Japan). Thermal cycling consisted of 95°C 
for 15 s, followed by 45 cycles at 95°C for 5 s and 60°C for 
30 s. Values were normalized to the expression of the actin 
gene using the 2∆∆Ct method. The following primers were 
used: MRP4, forward, 5-GTTCTTCTGGTGGCTCAAT- 
CC-3; reverse, 5-GGCTTCTGTGCGTCATTCTC-3, 
fragment size 168 bp; actin, forward, 5-GGCGGCACCA- 
CCATGTACCCT-3; reverse, 5-AGGGGCCGGACTCG- 
TCATACT-3, fragment size 202 bp. 
1.7  Western blot analysis 
Cells were harvested 7 d after transfection and washed 
twice in PBS. Cell pellets were lysed by sonication in lysis 
buffer (100 mmol/L Tris-HCl, pH 6.8, 4% SDS, 2% mer-
captoethanol, 10% glycerol). The lysates were cleared by 
centrifugation and the supernatant protein concentration was 
measured using a BCA Protein Assay Kit (HyClone-Pierce, 
Nanjing, China). Total cell lysates (2 g/L) were boiled 
with SDS-sample buffer (100 mmol/L Tris-HCl, pH 6.8, 4% 
SDS, 20% glycerol, 2% mercaptoethanol and 0.4% 
bromphenol blue), separated on 8% sodium dodecyl sulfate 
(SDS)-PAGE gels and then transferred to polyvinylidene 
difluoride (PVDF) membranes. After blocking with 5% 
skimmed milk in PBS, membranes were probed with mouse 
anti-GAPDH (Santa Cruz, USA) or mouse anti-MRP4 
(Abcam, Massachusetts, USA) antibodies followed by in-
cubation with horseradish peroxidase-conjugated goat an-
ti-mouse secondary antibodies. Finally, proteins were de-
tected using ECL Plus (Amersham, UK) and X-OMAT film 
(Kodak, USA). 
1.8  MTS assay  
Cell viability experiments were performed using the MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)- 
2-(4-sulfophenyl)-2H-tet-razolium) dye reduction assay 
(Cell Titer 96Aqueous One Solution Cell Proliferation Assay, 
Promega, China). Six groups of cells were assayed: control 
cells, lv-shRNA-NC cells, lv-shRNA-MRP4 cells (CON, 
NC, KD), with or without exposure to an IC50 dose (60 
µg/mL) of adriamycin (CON+ADR, NC+ADR, KD+ADR). 
Cells (2×104 cells/well) were seeded in triplicate in 96-well 
plates and assays were performed at 24 and 48 h. At each 
time point, MTS solution was added to wells in a 1:5 ratio 
and allowed to incubate for 3 h at 37°C in 5% CO2-humidi- 
fied atmosphere. Wells were then analyzed with a plate 
reader to detect absorbance at 490 nm.  
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1.9  Flow cytometric apoptosis assay 
The percentage of apoptotic cells was determined on a 
FACSCalibur flow cytometer (BD, New Iersey, USA). An-
nexin V-FITC (fluorescein isothiocyanate)/PI (propidium 
iodide) analysis was performed according to the manufac-
turer’s protocol (Annexin V­APC Apoptosis Detection Kit, 
eBioscience, USA). Approximately 1×105 cells/well were 
plated in triplicate in 6-well tissue culture plates. The same 
experimental groups used in the MTS assay were used in 
the flow cytometry assay. Cells were washed with PBS and 
resuspended in 100 µL Annexin V/PI incubation buffer and 
incubated for 15 min at room temperature in the dark. 
Binding buffer (400 µL) was then added to each sample and 
flow cytometry was performed. 
1.10  Statistical analysis 
All experiments were performed at least 3 times and statis-
tical analysis was performed using the SPSS13.0 package 
(SPSS, Chicago, USA). Data are expressed as the mean ± 
SD. An ANOVA test was used for the comparison of more 
than 2 groups. P values of less than 0.05 (P < 0.05) were 
considered to be statistically significant. 
2  Results 
2.1  Lentivirus-mediated high-efficiency infection of 
K562/ADR cells for knockdown of MRP4  
The infection efficiency of K562/ADR cells was over 80 
percent (Figure 2). Infected K562/ADR cells were analyzed  
 
 
Figure 2  Fluorescence images of GFP and phase contrast images of the 
same fields. CON, K562/ADR cells without infection; NC, K562/ADR 
cells infected with lv-shRNA-NC; KD, K562/ADR cells infected with 
lv-shRNA-MRP4. Magnification: × 200. 
by real-time PCR and Western blot analysis. Cell viability 
and apoptosis were determined by the MTS assay and flow 
cytometry, respectively. 
2.2  Decrease of MRP4 mRNA levels in human colon 
cancer RKO cells 
We tested the efficiency and specificity of the 5 lv-shRNA- 
MRP4 vectors in RKO cells. Previous studies have shown 
that RKO cells express a high level of MRP4 (data not 
shown). Subconfluent RKO cells were infected with either 
lv-shRNA-NC or with each of the lv-shRNA-MRP4 vectors. 
Five days post-infection, infected RKO cells and control 
cells were collected and MRP4 expression was determined 
by real-time PCR. As shown in Figure 3, infection of all 5 
lv-shRNAs-MRP4 vectors resulted in a considerable de-
crease in the levels of MRP4 mRNA compared with that of 
control and lv-shRNA-NC cells (P<0.05), while the expres-
sion was similar between the control and lv-shRNA-NC 
cells (P>0.05). The gene silencing induced by lv-shRNA1- 
MRP4 was greater (>80%) than that of the other lv-shRNA- 
MRP4 vectors. Therefore, lv-shRNA1-MRP4 was used for 
the subsequent experiments in K562/ADR cells.   
2.3  Inhibition of MRP4 mRNA and protein expression 
in K562/ADR cells 
To determine the effect of lv-shRNA1-MRP4 on the ex-
pression of MRP4 in K562/ADR cells, mRNA and protein 
levels were analyzed. K562/ADR cells were infected with 
either lv-shRNA-NC or lv-shRNA1-MRP4. Five days post- 
infection, cells were collected and MRP4 mRNA levels 
were detected by real-time PCR. Seven and 8 d post-   
infection, cells were collected and protein levels were de-
tected by Western blot analysis. Lv-shRNA1-MRP4-   
infected cells displayed a remarkable reduction in MRP4 
mRNA levels (Figure 4(a)). The level of MRP4 mRNA in 
lv-shRNA1-MRP4 cells (0.115±0.005) was lower than that 
of lv-shRNA-NC cells (1.001±0.051) and control cells 
 
 
Figure 3  Decrease of MRP4 mRNA levels in RKO cells detected by 
real-time PCR using the 2∆∆Ct method. CON, control cells; NC, lv-shRNA- 
NC cells; KD1, lv-shRNA1-MRP4 cells; KD2, lv-shRNA2-MRP4 cells; 
KD3, lv-shRNA3-MRP4 cells; KD4, lv-shRNA4-MRP4 cells; KD5, 
lv-shRNA5-MRP4 cells.  
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Figure 4  Reduction of MRP4 mRNA and protein levels in K562/ADR cells. (a) Changes in MRP4 mRNA levels detected by real-time PCR using the 
2∆∆Ct method. (b) Knockdown of MRP4 protein, assayed by Western blot analysis. CON, control cells; NC, lv-shRNA-NC cells; KD1, lv-shRNA1-MRP4 
cells; GAPDH, internal control protein. 
(0.758±0.108) (P<0.05). Consistent with the reduced level 
of MRP4 mRNA, lv-shRNA1-MRP4 infection resulted in a 
marked reduction of MRP4 protein levels at 7 and 8 d post- 
infection (Figure 4(b)). Western blot analysis demonstrated 
loss of MRP4 protein expression in K562/ADR cells treated 
with lv-shRNA1-MRP4. The MRP4 protein level was not 
affected in either the control or the lv-shRNA-NC-infected 
cells. 
2.4  Inhibition of MRP4 increases cell death in K562/ 
ADR cells 
MTS cell viability assays were performed to determine 
whether knockdown of MRP4 increased K562/ADR cell 
death. Lv-shRNA1-MRP4, lv-shRNA-NC and control cells 
were assayed 24 and 48 h after an IC50 dose of adriamycin 
(Figure 5). The combination of lv-shRNA1-MRP4 and 
adriamycin had a significantly greater repressive effect on 
cell viability than each of the other treatments (P < 0.05). 
That is, 48 h after infection, the survival of lv-shRNA1- 
MRP4, lv-shRNA-NC and control cells exposed to adri-
amycin was 47.7%, 76.3% and 79.1% (normalized to con-
trol cells), respectively. Lv-shRNA1-MRP4 or lv-shRNA- 
NC alone did not significantly inhibit cell proliferation 
compared to control cells (P > 0.05). 
2.5  Inhibition of MRP4 sensitizes K562/ADR cells to 
adriamycin-induced apoptosis 
To explore whether loss of MRP4 resulted in increased 
adriamycin-induced apoptosis, K562/ADR cells were in-
fected with lv-shRNA-NC or lv-shRNA1-MRP4. All cells 
(including control cells) were harvested for the assay 24 h 
after exposure to an IC50 dose of adriamycin, as described in 
Materials and methods. Annexin-V and PI staining were 
used to detect apoptotic cells, including cells in early-stage 
apoptosis (AV+/PI–) and late-stage apoptosis (AV+/PI+). As 
shown in Figure 6, the combination of lv-shRNA1-MRP4 
infection and adriamycin exposure resulted in a significant 
increase in apoptosis as compared to each treatment alone 
(P<0.05). A significant increase in the number of apoptotic 
cells was observed in control, lv-shRNA-NC and lv-shRNA1- 
MRP4 cells treated with adriamycin (11.37%, 10.74% and 
17.9%, respectively) as compared to control cells (8.03%), 
lv-shRNA-NC (7.94%) and lv-shRNA1-MRP4 (8.23%) 
cells without adriamycin treatment (P<0.05), while apopto-
sis was similar in control, lv-shRNA-NC and lv-shRNA1- 




Figure 5  Inhibition of MRP4 expression increases cell death in K562/ADR cells. MTS assays were performed to measure cell viability after MRP4 
knockdown and adriamycin treatment. K562/ADR cells were exposed to an IC50 dose of adriamycin 24 and 48 h after infection with lv-shRNA1-MRP4 or 
lv-shRNA-NC. CON, control cells; NC, lv-shRNA-NC cells; KD1, lv-shRNA1-MRP4 cells; CON+ADR, control cells treated with adriamycin; NC+ADR, 
lv-shRNA-NC cells treated with adriamycin; KD1+ADR, lv-shRNA1-MRP4 cells treated with adriamycin. 
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Figure 6  Inhibition of MRP4 sensitizes K562/ADR cells to apoptosis induced by adriamycin. (a) Cells were infected with lv-shRNA-NC or 
lv-shRNA1-MRP4 and treated with adriamycin for 24 h. Flow cytometric analysis after Annexin-V-PI staining was performed to evaluate the percentage of 
Annexin-V-PI positive cells. (b) Percentage of apoptotic cells, including both early-stage (AV+/PI) and late-stage (AV+/PI+) apoptosis. CON, control cells; 
NC, lv-shRNA-NC cells; KD1, lv-shRNA1-MRP4 cells; CON+ADR, control cells treated with adriamycin; NC+ADR, lv-shRNA-NC cells treated with 
adriamycin; KD1+ADR, lv-shRNA1-MRP4 cells treated with adriamycin.  
3  Discussion 
Leukemia is one of the most common diseases in hematol-
ogy. It shows frequent recurrence and a poor outcome de-
spite combined chemotherapy because of the multi-drug 
resistance of leukemia cells [20–22]. Improving sensitivity 
of leukemia cells to chemotherapy is crucial for curing leu-
kemia. 
Adriamycin is a standard anthracycline anticancer agent 
for treating AML patients and is classified as a topoisomer-
ase II inhibitor that induces cancer cells to undergo apopto-
sis by causing double-strand DNA breaks. Therefore, re-
sistance to adriamycin in leukemia cells is a major obstacle 
to achieving treatment success. Adriamycin resistance may 
often result from over-expression of P-glycoprotein (P-gp), 
which is encoded by the multidrug resistance 1 gene 
(MDR-1). However, increased expression of MDR-1 does 
not always contribute to clinical resistance, at least in leu-
kemia patients. The multifaceted nature of cellular re-
sistance led to the discovery of the MRP genes. The MRP 
family is composed of 9-related ABC transporters that are 
able to transport structurally diverse lipophilic anions and 
that function as drug efflux pumps. In cultured cell lines, 
expression of various MRPs confers resistance to natural 
product anticancer drugs [23]. Studies have shown that 
MRPs may also contribute to anthracycline resistance in 
AML [3]. Furthermore, as yet unidentified MRP homo-
logues that act as transporter proteins may play a role in 
MDR in AML. The presence of these nine transporters, and 
the finding that the lack of one transporter can be compen-
sated for by the other transporters, may account for the 
somewhat disappointing results in some clinical studies 
using only P-gp inhibitors. MRP4 exports organic anions, 
including endogenous and exogenous substances, and is 
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involved in MDR [4]. Several studies have shown that 
MRP4 is over-expressed in neuroblastoma and in the CEM- 
MP5 leukemia cell line and MRP4 is also a marker for im-
mature stem cells in leukemia patients. In addition, in-
creased levels of MRP5 mRNA were observed in SBC-3/ 
ADR, MCF7/ADR and K562/ADR cell lines as compared 
with the respective parental cells, and MRP5 is a candidate 
gene for adriamycin resistance in addition to MDR1 [24]. 
Amino acid sequence analysis has revealed that the nine 
transporters are composed of two nucleotide binding   
domains (NBDs) and at least two membrane spanning  
domains. MRP4, similar to MRP5, contains only two mem-
brane spanning domains and is the most recently character-
ized transporter [25]. These data indicate that MRP4 may 
also be involved in resistance to adriamycin chemotherapy. 
Thus, we used K562/ADR cells as a model of drug-resistant 
leukemia because of the elevated expression of MRP4 as 
compared to the parental K562 cells. This observation sug-
gests that MRP4 may be responsible for the adriamycin 
resistance in adriamycin-resistant acute myeloid leukemia 
cells. 
SiRNA has become a powerful tool in molecular biology 
research [26]. Double stranded RNA (dsRNA) is processed 
into 21 to 28 nucleotide siRNAs, which are then incorpo-
rated into a complex that binds homologous target RNAs. 
The target RNAs then ultimately undergo cleavage leading 
to gene silencing. The sequence specific manner with which 
siRNAs bind mRNA has opened the door to the possibility 
of using this technique in a model of cancer therapeutics 
[27–29]. While direct use of siRNA is simple and results in 
functional gene silencing, its effect is transient. DNA-based 
RNAi has the potential of being stably introduced when 
used in a gene therapy context, allowing in principle, a sin-
gle treatment of viral vector-delivered shRNA genes. Lenti-
virus vector-mediated gene transfer has some advantages 
for gene therapy: high efficiency of gene transfer into a 
wide variety of cells, including both dividing and non-  
dividing cells, long-term infection due to gene integration 
into the chromosome of host cells, no toxicity and no im-
mune response [30–35]. Moreover, the RNAi pathway is 
functional in human myeloid leukemia cell lines, providing 
a means to overcome the resistance to chemotherapeutic 
agents and ultimately to augment the efficacy of chemo-
therapy in myeloid leukemia [13]. Therefore, we used lenti-
virus-mediated siRNA to study the functions of MRP4 in 
K562/ADR cells.  
In the present study, we initially constructed 5 recombi-
nant lv-shRNA-MRP4 plasmids. The lv-shRNA1-MRP4 
plasmid was selected for subsequent experiments over the 
other four constructs because of its superior gene silencing 
efficacy; it could efficiently inhibit MRP4 mRNA and pro-
tein expression in K562/ADR cells. Then, we determined 
cell viability using the MTS assay. The viability of K562/ 
ADR cells was significantly reduced after combined 
lv-shRNA1-MRP4 infection and adriamycin treatment. To 
explore the mechanism of this reduced cell viability, flow 
cytometric analysis of apoptosis was performed. Knock-
down of MRP4 by lv-shRNA1-MRP4 sensitized K562/ 
ADR cells to adriamycin-induced apoptosis. Notably, a 
similar level of apoptosis was observed between the control, 
lv-shRNA-NC and lv-shRNA1-MRP4 cells, suggesting that 
silencing MRP4 alone did not induce apoptosis or reduce 
K562/ADR cell viability. These data indicate that reduced 
cell viability was due to apoptosis induced by adriamycin 
and that the combination of adriamycin treatment with 
MRP4 depletion by lv-shRNA1-MRP4 may be a potential 
approach to AML therapy. MRP4 is a membrane-embedded 
transporter molecule, which can act as an energy-dependent 
xenobiotic eﬄux pump [36], the transport activity of which 
results in decreased intracellular concentrations of anti-
cancer drugs, including adriamycin. Thus, the specific inhi-
bition of MRP4 by lentivirus-mediated siRNA results in the 
re-sensitization of K562/ADR cells to treatment with adri-
amycin.  
It is known that glutathione (GSH) is involved in a num-
ber of biochemical processes and its levels in various cellu-
lar compartments are tightly controlled. The two primary 
mechanisms by which cells regulate intracellular GSH  
levels are by altering the rate of its biosynthesis and the rate 
of GSH export from cells. There is growing evidence that 
some of the MRPs are involved in GSH export and are ma-
jor contributors to this process in cell models. Previous 
studies have demonstrated that drug-resistant cancer cells 
exhibit an elevated level of GSH compared to the drug- 
sensitive parental cells [37] and increased levels of a cispla-
tin-GSH conjugate have been detected in various cispla-
tin-resistant cell lines [38]. These data indicate that GSH 
may be associated with MDR in drug-resistant cancer cells. 
Supporting evidence has shown that GSH-conjugates are 
one of the main substrates for MRP4 [1]. It is not known 
whether the levels of cellular GSH are high or whether GSH 
is required for the transport of adriamycin in K562/ADR 
cells. In addition to its role as an efflux pump, MRP4 may 
contribute to adriamycin resistance in K562/ADR cells in 
other ways. Thus, further experiments are required to ex-
plore the function of MRP4 in these cells.  
One potential pitfall of the present study was only focus-
ing on the K562/ADR cell line, which is commonly used as 
an adriamycin-resistant leukemia model. Further observa-
tions with other cell lines would strengthen the significance 
of our study. Another potential problem is that endoge-
nously expressed shRNA may induce a toxic effect [39]. 
Therefore, future studies will need to focus on the develop-
ment of in vivo models.  
In conclusion, we show for the first time that MRP4, in 
addition to MDR1, is likely to be involved in adriamycin 
resistance in K562/ADR cells. We successfully knocked 
down MRP4 in K562/ADR cells using lentivirus-mediated 
siRNA, which resulted in increased adriamycin-induced 
apoptosis and decreased cell viability, raising the possibility 
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that an appropriate combination of adriamycin application 
with MRP4 depletion may be a promising approach for the 
treatment of AML. 
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